Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

TrendEli Aug. 22 at 5:24 AM

$NNVC NanoViricides develops nanomedicine virus treatments with early stage research and regulatory uncertainty

0 · Reply

Love1010 Aug. 20 at 3:41 PM

$NNVC an amazing cratering!!!! Africa news out?

0 · Reply

Love1010 Aug. 19 at 5:56 PM

$NNVC everytime Diwan does a PR, the stock sells off. Noone believes the hype.

0 · Reply

STRAYNUT Aug. 18 at 6:40 PM

$NNVC A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/a-drug-that-could-reduce-metastatic-cancer-resurgence-due-to-its-anti-1061948

0 · Reply

DonCorleone77 Aug. 18 at 12:49 PM

$NNVC NanoViricides says NV-387 could help reduce metastatic cancer resurgence

1 · Reply

DavidScott Aug. 18 at 3:42 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $GOVX $NMAX $HOLO $GME $NNVC

0 · Reply

STRAYNUT Aug. 16 at 10:59 PM

$NNVC NanoViricides, Inc. Common Stock (NNVC) Institutional Holdings NNVC Institutional Holdings Ownership Summary Institutional Ownership 8.30% https://www.nasdaq.com/market-activity/stocks/nnvc/institutional-holdings?page=1&rows_per_page=10

0 · Reply

Chamath_Palihapiteeznuts Aug. 15 at 2:11 PM

$NNVC ST is literally pumping this stock. I keep getting emails. It’s weird

1 · Reply

Tohuwabohu Aug. 15 at 1:26 PM

$NNVC not sure if fake bears wanna make me sell or fake bulls wanna make me hold - buts once a catalyst sets in i am settled!

0 · Reply

Love1010 Aug. 14 at 6:02 PM

$NNVC there is a reason the sellers always come back. Nobody wants to hold shite.

0 · Reply

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 25 days ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 4 weeks ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 4 weeks ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 5 weeks ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 2 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 2 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 3 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 3 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 3 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 3 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 4 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 4 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 5 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 6 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 6 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 6 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 7 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 7 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 7 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 8 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 8 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 10 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 10 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 10 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 11 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 11 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 11 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 11 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Feb 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Feb 1, 2024, 6:20 AM EST - 1 year ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Jan 29, 2024, 6:30 AM EST - 1 year ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

TrendEli Aug. 22 at 5:24 AM

$NNVC NanoViricides develops nanomedicine virus treatments with early stage research and regulatory uncertainty

0 · Reply

Love1010 Aug. 20 at 3:41 PM

$NNVC an amazing cratering!!!! Africa news out?

0 · Reply

Love1010 Aug. 19 at 5:56 PM

$NNVC everytime Diwan does a PR, the stock sells off. Noone believes the hype.

0 · Reply

STRAYNUT Aug. 18 at 6:40 PM

0 · Reply

DonCorleone77 Aug. 18 at 12:49 PM

$NNVC NanoViricides says NV-387 could help reduce metastatic cancer resurgence

1 · Reply

DavidScott Aug. 18 at 3:42 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $GOVX $NMAX $HOLO $GME $NNVC

0 · Reply

STRAYNUT Aug. 16 at 10:59 PM

0 · Reply

Chamath_Palihapiteeznuts Aug. 15 at 2:11 PM

$NNVC ST is literally pumping this stock. I keep getting emails. It’s weird

1 · Reply

Tohuwabohu Aug. 15 at 1:26 PM

$NNVC not sure if fake bears wanna make me sell or fake bulls wanna make me hold - buts once a catalyst sets in i am settled!

0 · Reply

Love1010 Aug. 14 at 6:02 PM

$NNVC there is a reason the sellers always come back. Nobody wants to hold shite.

0 · Reply

STRAYNUT Aug. 13 at 3:14 PM

$NNVC Is the US in a Summer COVID Surge? Cases Are Rising in These States https://www.today.com/health/coronavirus/covid-2025-summer-surge-rcna218754

0 · Reply

Love1010 Aug. 12 at 7:20 PM

$NNVC dribble dribble dribble. No news out of Africa. Or perhaps hiding the bad news for now.

0 · Reply

STRAYNUT Aug. 12 at 12:00 AM

$NNVC Short Interest (07/31/25) Shares Sold Short 84,921 Change from Last -19.86% Percent of Float 0.55% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

Love1010 Aug. 11 at 4:17 PM

$NNVC @STRAYNUT You should not trust this guy at all. Look at his calls over the years ...truly embarrassing. A monkey throwing a dart could do better than his picks. A decade long bagholder during the biggest bull market in history!!!!

0 · Reply

STRAYNUT Aug. 7 at 10:32 PM

$$NNVC Just in case you missed these posts.. @ Straynut: July 22, 2025: Regarding the invested capital of $150 million, the current market value of Nano is roughly $25 million, which is the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making, is ZERO. NONSENSE!

0 · Reply

STRAYNUT Aug. 7 at 10:30 PM

$NNVC @ Straynut: July 22, 2025: It gets even better! "NV-387 is expected to become an "emperic therapy" for any/all viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection". (NNVC PR of 5-28-2025.)

0 · Reply

STRAYNUT Aug. 6 at 5:23 PM

$NNVC INNOVATIVE VIRAL THERAPEUTICS Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several diseases: NV-387 combats RSV, COVID-19, Flu/Bird Flu and Smallpox/Monkeypox; NV-HHV-1 combats Shingles and others in the Herpes Family; other Nanoviricides™ combat other diseases like Dengue, Rabies, and Ebola/Marburg. This versatility exploits a feature common to all pathogenic viruses. https://www.nanoviricides.com/

0 · Reply

Love1010 Aug. 1 at 6:34 PM

$NNVC brilliance again

0 · Reply

Love1010 Aug. 1 at 6:15 PM

$NNVC the pumps get smaller and the dumps go deeper....this is the process of a company in the demise. You will see pennies forever at some point n

0 · Reply

Love1010 Jul. 31 at 5:44 PM

$NNVC if you aren't seeing the bearish signals and change in trend, you aren't seeing!!

0 · Reply

Kewlpapa Jul. 30 at 8:08 PM

$NNVC picked up some shares today. Will continue to accumulate here

1 · Reply

The_Titan_Traders Jul. 30 at 3:01 PM

$NNVC long

1 · Reply

Market Cap	23.14M
Revenue (ttm)	0.00
Net Income (ttm)	-8.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	110,000
Avg Vol	246,994
Day's Range	N/A - N/A
Shares Out	16.07M
Stochastic %K	43%
Beta	0.96
Analysts	Strong Sell
Price Target	$6.50